Faculty profile

Marc Brisson

ResearcherMédecine sociale et préventiveUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Marc Brisson

Researcher

Médecine sociale et préventive

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
34 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2025.
Supervised 2 trainees who won CIHR awards, most recently in 2014.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Vaccination Dynamic Mathematical Modeling Public Health Epidemiology Health Inequalities Cervical Cancer Elimination Global Health Human Papillomavirus (Hpv)

Latest papers

Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025.
Expert review of vaccines · 2026
Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa: Results From Two Mathematical Models.
Journal of the International AIDS Society · 2026
Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
Lancet (London, England) · 2026 · first author

All 90 publications

Latest funding

Developing multi-virus transmission-dynamic models and mixing matrices using insights from temporal variations in infection and contact patterns before, during, and after the COVID-19 pandemic: Learning from the past to prepare for the future
CIHR · 2025 · Nominated PI
$298,350
Canada Research Chair - Tier 1
CIHR · 2024 · Nominated PI
$1,400,000
Optimizing HPV vaccination programs in Low- and Middle-Income Countries (LMIC) and Canada to reduce inequalities and reach global elimination of cervical cancer: An integrated knowledge translation dynamic-modeling approach
CIHR · 2024 · Nominated PI
$902,701

All 12 grants and awards

90 publications.

Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025.

Suh J, Brisson M, Burger EA, Kim JJ, Laprise JF, Jit M

Expert review of vaccines2026

DOI: 10.1080/14760584.2026.2736328 PMID: 42770688

Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa: Results From Two Mathematical Models.

Doyle CM, Rönn MM, van Schalkwyk C, Brisson M, Soni N, Boily MC, Maheu-Giroux M

Journal of the International AIDS Society2026

DOI: 10.1002/jia2.70149 PMID: 42499184

Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.

Brisson M, Drolet M, Gingras G, Laprise JF, Chamberland É, Bruni L, Sabourin AA, Bénard É, Ndiaye C, Barnabas RV

Lancet (London, England)2026First author

DOI: 10.1016/s0140-6736(26)00410-1 PMID: 42070573

Single-dose HPV vaccination in the United States - a multi-modeling analysis.

Burger EA, Laprise JF, Spencer JC, Sy S, Regan MC, Drolet M, Chamberland É, Brisson M, Kim JJ

Lancet regional health. Americas2026

DOI: 10.1016/j.lana.2025.101361 PMID: 41586382

Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis.

Bénard É, Drolet M, Gingras G, Laprise JF, Sabourin AA, Bloem P, Akaba H, Brotherton J, Jit M, Brisson M

The Lancet. Global health2025Senior author

DOI: 10.1016/s2214-109x(25)00376-6 PMID: 41240953

Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.

Laprise JF, Chesson HW, Markowitz LE, Drolet M, Brisson M

Annals of internal medicine2025Senior author

DOI: 10.7326/annals-25-03470 PMID: 41248506

Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort study.

Middeldorp M, Donken R, Nirmal A, Smith B, Citlali Marquez A, Bettinger JA, Brisson M, Burchell AN, Dobson SR, Dawar M, Franco EL, Grennan T, Krajden M, Mayrand MH, McNeil S, Naus M, Sauvageau C, Singer J, Smith LW, Ogilvie GS, Sadarangani M

BMJ open2025

DOI: 10.1136/bmjopen-2025-100560 PMID: 41027698

Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.

Laprise JF, Chesson HW, Markowitz LE, Drolet M, Brisson M

Annals of internal medicine2025Senior author

DOI: 10.7326/m24-0421 PMID: 39586101

Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling.

Brisson M, Laprise JF, Drolet M, Chamberland É, Bénard É, Burger EA, Jit M, Kim JJ, Markowitz LE, Sauvageau C, Sy S

Journal of the National Cancer Institute. Monographs2024First author

DOI: 10.1093/jncimonographs/lgae038 PMID: 39529531

Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting.

Burger EA, Laprise JF, Portnoy A, Spencer JC, Sy S, Regan MC, Bénard É, Drolet M, Brisson M, Kim JJ

Journal of the National Cancer Institute. Monographs2024

DOI: 10.1093/jncimonographs/lgae039 PMID: 39529530

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Vaccination Dear Professor Brisson, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Developing multi-virus transmission-dynamic models and mixing matrices using insights from temporal variations in infection and contact patterns before, during, and after the COVID-19 pandemic: Learning from the past to prepare for the future" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Marc Brisson

Research

Latest papers

Latest funding

Global policy determinants of national human papillomavirus vaccine introductions in 2006-2025.

Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa: Results From Two Mathematical Models.

Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.

Single-dose HPV vaccination in the United States - a multi-modeling analysis.

Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis.

Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.

Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort study.

Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.

Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling.

Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting.

CANMOD: Canadian Network for Modelling Infectious Disease

Frequent collaborators

Gaston De Serres

Mathieu Maheu-Giroux

Denis Talbot

Sarah Wilson

Jonathan Gubbay

Shelly Bolotin

Todd Hatchette

Sharmistha Mishra

Michel Alary

Manish Sadarangani

James Wright

Mel Krajden

Gina Ogilvie

Rachel Savage

Laurent Azoulay

Ashleigh Tuite

Caroline Quach

Robert Platt

Bonnie Henry

David Fisman

Beate Sander

Nadine Kronfli

Tony Mazzulli

Natalie Prystajecky

Alexandre Bureau

Shelley Deeks

Brian Ward

Shelly McNeil

Christina Greenaway

Laurent Azoulay